Thermo Fisher Scientific (TMO) Equity Income (2021 - 2026)

Thermo Fisher Scientific (TMO) has reported Equity Income for 6 consecutive years, with -$8.0 million the latest figure, recorded in Q1 2026.

• Equity Income for Q1 2026 came in at -$8.0 million, up 42.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$36.0 million (up 54.43% YoY), and the FY2025 annual result was -$41.0 million, up 2.38% from the prior year.
• Equity Income was -$8.0 million for Q1 2026 at Thermo Fisher Scientific, up from -$32.0 million in the prior quarter.
• Over five years, Equity Income peaked at $33.0 million in Q4 2024 and troughed at -$84.0 million in Q2 2024.
• Average Equity Income over 5 years is -$19.0 million, with a median of -$16.0 million recorded in 2023.
• Year-over-year, Equity Income slumped 5000.0% in 2022 and surged 3400.0% in 2024.
• Over 5 years, Equity Income stood at -$30.0 million in 2022, then soared by 96.67% to -$1.0 million in 2023, then soared by 3400.0% to $33.0 million in 2024, then slumped by 196.97% to -$32.0 million in 2025, then jumped by 75.0% to -$8.0 million in 2026.
• Per Business Quant data, the three most recent Equity Income figures were -$8.0 million in Q1 2026, -$32.0 million in Q4 2025, and $2.0 million in Q3 2025.